estradiol

In the meantime, data from a European multicenter trial are building a strong case for a different device, the Aerodiol 17[beta]-estradiol nasal spray, as an alternative to oral ERT.

The patients, who had a mean age of 51, were randomized to receive either Aerodiol spray at a dose of 300 [micro]/day (one spray into each nostril) plus a daily placebo pill, or a placebo spray plus 2mg/day oral micronized 17[beta]-estradiol.

Severe mastalgia was less frequent in Aerodiol versus oral therapy with the incidence being 1% and 5.2%, respectively.